Equities Analysts Offer Predictions for CRBU FY2029 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Brookline Capital Management issued their FY2029 earnings per share estimates for Caribou Biosciences in a note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $16.92 for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Several other research analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a report on Friday, November 15th. Bank of America cut their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Citigroup dropped their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $10.33.

Caribou Biosciences Stock Down 8.0 %

Shares of NASDAQ CRBU opened at $1.72 on Wednesday. Caribou Biosciences has a twelve month low of $1.50 and a twelve month high of $8.33. The company’s fifty day moving average is $2.02 and its 200-day moving average is $2.00. The stock has a market cap of $155.75 million, a price-to-earnings ratio of -1.04 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.02 million for the quarter, compared to analyst estimates of $3.37 million.

Hedge Funds Weigh In On Caribou Biosciences

Hedge funds have recently made changes to their positions in the business. PFM Health Sciences LP grew its position in Caribou Biosciences by 5.5% in the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after purchasing an additional 223,299 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after buying an additional 536,162 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares in the last quarter. FMR LLC increased its position in shares of Caribou Biosciences by 7.4% in the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after acquiring an additional 109,606 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Caribou Biosciences during the second quarter worth about $2,432,000. 77.51% of the stock is owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.